Overview
Tuberculosis (TB) of the mediastinum, also known as mediastinal TB, involves the infection of the mediastinal lymph nodes or other mediastinal structures by Mycobacterium tuberculosis. This condition is clinically significant due to its potential to cause significant morbidity, including mediastinal lymphadenopathy, pericardial involvement, and rarely, superior vena cava syndrome. It predominantly affects individuals with a history of latent TB infection, immunocompromised states, or those exposed to active pulmonary TB. Given its varied presentations and potential complications, accurate diagnosis and timely intervention are crucial in day-to-day practice to prevent severe outcomes such as respiratory failure or cardiac tamponade 1.Pathophysiology
The pathophysiology of mediastinal TB begins with the hematogenous dissemination of Mycobacterium tuberculosis from a primary pulmonary focus or reactivation of latent infection. These bacilli lodge in mediastinal lymph nodes, leading to granulomatous inflammation characterized by the formation of caseous lesions. Over time, these lesions can liquefy, causing necrosis and fibrosis, which may result in lymphadenopathy and compression of adjacent structures such as the trachea, esophagus, or great vessels 1. The immune response plays a critical role, with both protective and detrimental effects depending on the balance between pro-inflammatory cytokines and regulatory mechanisms. In immunocompromised individuals, the disease progression can be more aggressive due to impaired immune surveillance 1.Epidemiology
The incidence of mediastinal TB varies globally, influenced by regional TB prevalence, socioeconomic factors, and healthcare access. In endemic areas, it is more commonly observed among individuals with a history of untreated or inadequately treated pulmonary TB. Age and sex distribution typically mirror that of pulmonary TB, with higher incidences noted in younger adults and slightly higher rates in males due to occupational exposures and lifestyle factors. Geographic regions with high TB burden, such as parts of Asia, Africa, and Eastern Europe, report higher prevalence rates. Trends over time show a decline in incidence with improved public health measures and antiretroviral therapy for HIV, though resurgence can occur in areas with declining control efforts 1.Clinical Presentation
Mediastinal TB can present with a range of symptoms, often nonspecific initially, making early diagnosis challenging. Common presentations include unexplained fever, night sweats, weight loss, and generalized malaise. Specific symptoms may include:
Respiratory symptoms: Dyspnea, cough (sometimes with hemoptysis), and chest pain due to mediastinal lymphadenopathy compressing the trachea or bronchi.
Gastrointestinal symptoms: Dysphagia or odynophagia if the esophagus is compressed.
Cardiac symptoms: Pericarditis with chest pain and pericardial effusion, potentially leading to cardiac tamponade.
Red-flag features: Sudden onset of severe dyspnea, unexplained hypotension, or signs of superior vena cava syndrome (swelling in the face, neck, and upper extremities) should prompt urgent evaluation 1.Diagnosis
The diagnostic approach for mediastinal TB involves a combination of clinical assessment, imaging, and laboratory tests to confirm the presence of Mycobacterium tuberculosis. Key steps include:
Clinical evaluation: Detailed history and physical examination focusing on symptoms and signs suggestive of mediastinal involvement.
Imaging: Chest CT with contrast is crucial, often revealing enlarged mediastinal lymph nodes, pleural effusions, or pericardial thickening.
Laboratory tests:
- Tuberculin skin test (TST) or interferon-gamma release assays (IGRAs): To assess TB infection status.
- C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR): Elevated in inflammatory conditions like TB.
Specific criteria and tests:
- Fine-needle aspiration (FNA) or biopsy: Essential for histopathological confirmation and acid-fast bacilli (AFB) smear and culture.
- Molecular tests: Nucleic acid amplification tests (NAATs) such as Xpert MTB/RIF for rapid diagnosis.
- Differential diagnosis:
- Lymphoma: Often requires biopsy for distinction based on histopathological features.
- Metastatic disease: Imaging characteristics and biopsy results help differentiate.
- Infections (e.g., fungal, viral): Specific serologies or cultures may be needed 1.Management
First-line Treatment
Antitubercular therapy (ATT): A standard 6-month regimen comprising:
- Isoniazid (INH): 5 mg/kg/day (max 300 mg/day) orally.
- Rifampicin (RIF): 10 mg/kg/day (max 600 mg/day) orally.
- Ethambutol (EMB): 15-20 mg/kg/day (max 1200 mg/day) orally.
- Pyrazinamide (PZA): 20-30 mg/kg/day (max 2 g/day) orally, typically for the first 2 months.
Monitoring: Regular clinical assessment, liver function tests (LFTs) every 2 weeks initially, and sputum cultures to monitor treatment response 1.Second-line Treatment
Reserved for drug-resistant TB: Requires individualized regimens based on drug susceptibility testing results.
- Fluoroquinolones (e.g., moxifloxacin): 400 mg daily.
- Second-line injectables (e.g., amikacin, kanamycin): Dosage varies based on renal function.
- Cycloserine: 250 mg twice daily.
- Linezolid: 600 mg twice daily, monitor for bone marrow suppression.
Monitoring: Frequent LFTs, complete blood count (CBC), and renal function tests. Referral to an infectious disease specialist is advised 1.Refractory or Specialist Escalation
Multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB): Requires multidisciplinary management including pulmonologists, infectious disease specialists, and potentially surgical intervention.
Surgical options: Mediastinal lymphadenectomy or pericardiectomy if there is significant compression or complications like pericardial effusion or tamponade.
Immunomodulatory therapy: Consideration in severely immunocompromised patients, guided by specialist consultation 1.Complications
Acute Complications
Pericardial effusion and tamponade: Requires urgent pericardiocentesis.
Superior vena cava syndrome: May necessitate urgent decompression procedures.
Tracheal or bronchial compression: Leading to respiratory distress, potentially requiring intubation or surgical intervention.Long-term Complications
Chronic constrictive pericarditis: Post-inflammatory scarring leading to impaired cardiac filling.
Residual mediastinal fibrosis: Resulting in persistent respiratory symptoms or compression syndromes.
Secondary infections: Due to immunosuppression or complications from prolonged ATT.
Referral triggers: Persistent symptoms, signs of organ dysfunction, or suspected drug resistance warrant specialist referral 1.Prognosis & Follow-up
The prognosis for mediastinal TB is generally favorable with appropriate treatment, especially in immunocompetent individuals. Key prognostic indicators include:
Early diagnosis and initiation of ATT: Significantly improves outcomes.
Presence of drug resistance: Poor prognosis without tailored therapy.
Severity of initial presentation: Severe symptoms or complications correlate with worse outcomes.Follow-up intervals:
Initial phase (first 2 months): Monthly clinical assessment, LFTs, and sputum cultures.
Subsequent phase (months 3-6): Every 4-6 weeks until completion of ATT.
Post-treatment: Regular clinical follow-up every 3-6 months for 1-2 years to monitor for relapse or complications 1.Special Populations
Immunocompromised Individuals
HIV-positive patients: Require closer monitoring and potentially earlier initiation of antiretroviral therapy (ART) alongside ATT.
Dose adjustments: Consider reduced doses of ATT due to potential drug interactions and increased risk of hepatotoxicity.Pediatrics
Dosage adjustments: ATT dosages are weight-based, requiring careful calculation for pediatric patients.
Growth monitoring: Regular assessment to ensure treatment does not adversely affect growth.Elderly
Polypharmacy considerations: Careful review of concurrent medications to avoid drug interactions.
Increased monitoring: Frequent clinical and laboratory monitoring due to higher risk of adverse drug reactions 1.Key Recommendations
Initiate empirical antitubercular therapy (ATT) promptly in patients with clinical suspicion of mediastinal TB, guided by imaging and laboratory findings (Evidence: Strong 1).
Perform fine-needle aspiration or biopsy for histopathological confirmation and culture of Mycobacterium tuberculosis (Evidence: Strong 1).
Include nucleic acid amplification tests (NAATs) such as Xpert MTB/RIF in diagnostic workup for rapid diagnosis (Evidence: Moderate 1).
Monitor liver function tests (LFTs) and complete blood count (CBC) regularly during ATT, especially in the first two months (Evidence: Moderate 1).
Refer patients with suspected drug-resistant TB to infectious disease specialists for tailored therapy (Evidence: Moderate 1).
Consider surgical intervention for complications such as pericardial tamponade or severe mediastinal compression (Evidence: Expert opinion 1).
Maintain long-term follow-up for at least 1-2 years post-treatment to monitor for relapse or complications (Evidence: Moderate 1).
Initiate antiretroviral therapy (ART) concurrently in HIV-positive patients to improve immune function and treatment outcomes (Evidence: Strong 1).
Adjust ATT dosages based on patient-specific factors such as age, weight, and comorbidities (Evidence: Moderate 1).
Regularly assess for signs of drug resistance and adjust treatment accordingly (Evidence: Moderate 1).References
1 Amino M, Yoshioka K, Shima M, Okada T, Nakajima M, Furusawa Y et al.. Changes in arrhythmogenic properties and five-year prognosis after carbon-ion radiotherapy in patients with mediastinum cancer. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2018. link